Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biocorp
Private Company Edition: Publicly held Ascendis outsourced its preclinical AMD program to private Eyconis. Also, Innovation Endeavors revealed a new $630m VC fund and Mirae raised $50m for its first life science fund, while Accent, Comanche and Tr1X each brought in $75m rounds.
Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.
After a nearly two-year collaboration, Novo Nordisk said it has begun talks to buy a controlling stake in French medical device company Biocorp.
Emerging Company Profile: The US biotech’s Trillium platform, which has caught the eye of Bayer, could enhance radioligand pharmacokinetics and bioavailability while reducing side effects, enabling the development of both therapeutics and imaging compounds.
- Contract Research Organization-CRO
- Digital Health
- Medical Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.